@prefix dcterms: .
@prefix foaf: .
@prefix wdrs: .
@prefix owl: .
@prefix xsd: .
@prefix gr: .
@prefix xml: .
@prefix vcard: .
@prefix dc: .
@prefix rdf: .
@prefix rdfs: .
@prefix pto: .
@prefix schema: .
# OWL DL work-arounds (instead of imports)
dc:contributor a owl:AnnotationProperty.
dc:creator a owl:AnnotationProperty.
dc:rights a owl:AnnotationProperty.
dc:subject a owl:AnnotationProperty.
dc:title a owl:AnnotationProperty.
dcterms:license a owl:AnnotationProperty.
wdrs:describedby a owl:AnnotationProperty.
foaf:Document a owl:Class.
foaf:homepage a owl:AnnotationProperty.
foaf:page a owl:AnnotationProperty.
foaf:primaryTopic a owl:AnnotationProperty.
schema:Product a owl:Class.
#OWL 1 DL compatibility of the OWL2 deprecated property
owl:deprecated a owl:AnnotationProperty.
a owl:Ontology;
dc:title "PTO: The Product Types Ontology for Semantic Web-based E-Commerce"@en;
rdfs:comment """The Product Types Ontology: Good identifiers for product types based on Wikipedia
This service provides GoodRelations-compatible class definitions for any type of product or service that has an entry in the English Wikipedia.
Vocabulary: http://www.productontology.org/#
Namespace: http://www.productontology.org/
The Product Types Ontology is designed to be used in combination with GoodRelations, a standard vocabulary for the commercial aspects of offers.
See http://purl.org/goodrelations/ for more information."""@en;
rdfs:label "The Product Types Ontology for Semantic Web-based E-Commerce"@en;
dc:contributor "The class abstracts and translations of labels are taken from Wikipedia, the free encyclopedia."@en;
dc:creator "Martin Hepp"@en;
dc:rights "The class definition texts are taken from Wikipedia, the free encyclopedia under a Creative Commons Attribution-ShareAlike 3.0 Unported (CC BY-SA 3.0) license, see http://creativecommons.org/licenses/by-sa/3.0/. Accordingly, all ontology class definitions provided in here are available under the very same license."@en;
dc:subject "E-Commerce, E-Business, GoodRelations, Ontology, Wikipedia, DBPedia"@en;
dcterms:license ;
rdfs:seeAlso ;
owl:imports ;
owl:versionInfo "2026-04-09T10:55:16.433344".
a foaf:Document;
foaf:primaryTopic .
a foaf:Document;
foaf:primaryTopic .
a foaf:Document;
foaf:primaryTopic .
a foaf:Document;
foaf:primaryTopic .
a owl:Class;
rdfs:subClassOf gr:ProductOrService, schema:Product;
rdfs:label "Anti-obesity medication"@en;
rdfs:comment """Anti-obesity medication or weight loss medications are pharmacological agents that reduce excess body fat and cause weight loss. These medications alter one of the fundamental processes of weight regulation, by: reducing appetite and consequently energy intake, increasing energy expenditure, redirecting nutrients from adipose to lean tissue, or interfering with the absorption of calories.
Weight loss drugs have been developed since the early twentieth century, and many have been banned or withdrawn from the market due to adverse effects, including deaths; other drugs proved ineffective. Although many earlier drugs were stimulants such as amphetamines, in the early 2020s, GLP-1 receptor agonists became popular for weight loss.
As of 2023, the medications liraglutide, naltrexone/bupropion, orlistat, semaglutide, tirzepatide and phentermine/topiramate are approved by the US Food and Drug Administration (FDA) for weight management in combination with reduced-calorie diet and increased physical activity. Medications to treat obesity may be considered in those with a body mass index above 30, or above 27 with obesity related complications (such as hypertension, hyperlipidemia, cardiovascular disease, or obstructive sleep apnea). As of 2022, no medication has been shown to be as effective at long-term weight reduction as bariatric surgery.
In 2026, the GLP-1 pills for obesity was launched into the market, serving as a more convenient alternative to the traditional injections. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk, and a rival oral drug from Eli Lilly is slated for a U.S. approval in the later part of 2026.
(Source: Wikipedia, the free encyclopedia, see http://en.wikipedia.org/wiki/Anti-obesity_medication)"""@en;
rdfs:isDefinedBy ;
rdfs:label "أدوية تخسيس"@ar;
rdfs:label "ادويه التخسيس"@arz;
rdfs:label "Medicament contra l'obesitat"@ca;
rdfs:label "Slankepille"@da;
rdfs:label "Antiadipositum"@de;
rdfs:label "داروی لاغری"@fa;
rdfs:label "Laihdutusvalmiste"@fi;
rdfs:label "Pengobatan antikegemukan"@id;
rdfs:label "Dimagrante"@it;
rdfs:label "Medicação contra obesidade"@pt;
rdfs:seeAlso ,
,
;
wdrs:describedby , ;
foaf:homepage ;
foaf:page .